New research article in The Lancet Microbe>

Effect of compensatory evolution in the emergence and transmission of #rifampicin-resistant #Mycobacterium #tuberculosis in Cape Town, #SouthAfrica: a genomic epidemiology study

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00110-6/fulltext

#TB #AMR

New research article in The Lancet Respiratory Medicine>

Completion, safety, and efficacy of #tuberculosis preventive treatment regimens containing #rifampicin or #rifapentine: an individual patient data network meta-analysis

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2823%2900096-6/fulltext

#TB

New research article in The Lancet Infectious Diseases>

#Rosuvastatin adjunctive therapy for #rifampicin-susceptible pulmonary #tuberculosis: a phase 2b, randomised, open-label, multicentre trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2823%2900067-1/fulltext

#TB

New research article in The Lancet> Evaluation of two short standardised regimens for the treatment of #rifampicin-resistant #tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02078-5/fulltext#.Y2tvg1KX-wU.twitter